On April 9, 2026 TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, reported its participation in the Society of Interventional Radiology (SIR) 2026 Annual Scientific Meeting, taking place April 11–15, 2026, in Toronto, Ontario, Canada.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
TriSalus will showcase new clinical and preclinical data highlighting the capabilities of its Pressure Enabled Drug Delivery (PEDD) platform to enhance therapeutic delivery across multiple disease states.
Featured presentations include:
April 13, 2026 | 12:10 PM ET
David Jaroch, PhD (TriSalus Life Sciences)
Poster Presentation:
Pressure Enabled Drug Delivery During Delivery of Embolic Spheres Enhances Hepatic Tumor Penetration in an Oncopig Model
April 13, 2026 | 3:18 PM ET
Adam Robinson, MS (Tulane University) and Richard Marshall, MD (Tulane University and TriSalus Life Sciences)
Scientific Session Presentation:
Embolization of Neuroendocrine Tumor Metastases to the Liver: A Single-Center Experience Before and After the Introduction of Pressure Enabled Drug Delivery
April 14, 2026 | 3:36 PM ET
Francis Kang, MD (Rutgers Robert Wood Johnson Medical School)
Scientific Session Presentation:
Novel Approaches to Uterine Artery Embolization: A Clinical Assessment of Safety and Efficacy Using a Pressure Enabled Drug Delivery Device
Additional abstracts and presentation materials are available at:
View Source
"These presentations continue to expand the growing body of evidence supporting PEDD as a differentiated approach to improving therapeutic delivery," said Mary Szela, Chief Executive Officer of TriSalus Life Sciences. "We are particularly encouraged by the breadth of applications—from liver-directed therapies to uterine artery embolization—demonstrating the versatility of our platform."
Richard Marshall, MD, Chief Medical Officer of TriSalus, added, "Our work reflects a broader commitment to advancing interventional oncology and embolization techniques. I am excited to see data ranging from pre-clinical to investigator-initiated studies in human subjects across multiple indications presented in this forum. By enabling more effective delivery of therapies, PEDD has the potential to improve outcomes across multiple indications and expand the treatment toolbox for interventional radiologists."
(Press release, TriSalus Life Sciences, APR 9, 2026, View Source [SID1234664282])